ZeroContrast
Iron
- Joined
- Mar 3, 2026
- Posts
- 431
- Reputation
- 293
(This is for informational purposes only.)
I will now go over each study I researched and explain how it contributes to the theory of Meclizine increasing height growth. (Keep in mind some of these studies aren't proof that this helps with height growth it just makes the explanation of how everything works easier for me.)
This isn't a meclizine study. I'm including it because it gives you a really useful "what successful FGFR3-targeted growth treatment looks like in humans" comparison.
Vosoritide works through a different pathway that essentially counteracts the downstream growth-suppressing effects of FGFR3.
In the study, growth velocity increased by roughly 1.3–2.1 cm/year above baseline at 6 months in several dose groups, and the increase was maintained for years. Height Z-scores also improved.
FGFR3 overactivity → MAPK pathway overactivity → growth-plate suppression
while CNP/vosoritide activates:
NPR-B → cGMP → PKG → inhibition of the FGFR3/MAPK growth-suppressing pathway
So you get:
less FGFR3 braking → more growth-plate activity → increased longitudinal bone growth → increased height.
That's conceptually similar to why meclizine is interesting, even though the molecular route is different.
And importantly, vosoritide provides actual human evidence that interfering with the FGFR3 growth-suppression pathway can increase linear growth.
So according to my research this definitely correlates with height, the issue is that there isn't enough evidence that meclizine inhibits FGFR3 strongly enough, long enough, in the right tissues to produce a meaningful increase in human standing height. Also according to my evidence you're highly likely to get a lot of arm-span growth while on meclizine.
There isn't an exact dosage you should take due to the lack of evidence but according to the studies, the theoretical best dosage for height growth would be somewhere around 25mg so I'd aim for there.
(You can dnr ts its just regular stores)
I don't know who said this but that's a myth meclizine doesn't cause permanent cognitive numbing it can cause drowsiness/somnolence temporarily.
What is Meclizine?
Meclizine also known as Bonine, is an antihistamine used to treat motion sickness and dizziness. It is taken by mouth. Effects usually begin in an hour and last up to a day. Meclizine can also theoretically be used for height growth by inhibiting a key signaling pathway involved in achondroplasia (ACH), which is what this guide is about. (if growth plates are open ofc)
I will now go over each study I researched and explain how it contributes to the theory of Meclizine increasing height growth. (Keep in mind some of these studies aren't proof that this helps with height growth it just makes the explanation of how everything works easier for me.)
Study: Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
What they found: Meclizine inhibited the abnormal FGFR3 signaling caused by the achondroplasia mutation and improved chondrocyte proliferation/differentiation.
Why that could mean more height:
The growth plates contain chondrocytes, which make cartilage that is progressively replaced by bone during longitudinal bone growth. In ACH, overactive FGFR3 acts like a brake on this process.
This is the mechanistic foundation for the entire meclizine theory. It doesn't prove that children get taller though this is just the foundation.
What they found: Meclizine inhibited the abnormal FGFR3 signaling caused by the achondroplasia mutation and improved chondrocyte proliferation/differentiation.
Why that could mean more height:
The growth plates contain chondrocytes, which make cartilage that is progressively replaced by bone during longitudinal bone growth. In ACH, overactive FGFR3 acts like a brake on this process.
This is the mechanistic foundation for the entire meclizine theory. It doesn't prove that children get taller though this is just the foundation.
Study: Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
What they found: Meclizine increased longitudinal skeletal growth in genetically modified mice carrying an ACH-like FGFR3 mutation.
Why that could mean more height:
This is the first big step beyond cells. Instead of merely showing that meclizine changes chondrocytes in a dish, they showed that an entire growing animal developed more longitudinal skeletal growth.
For humans, that would translate primarily into longer limbs and potentially greater standing height.
The important limitation: mice aren't humans, and a skeletal-growth effect in mice doesn't guarantee a clinically meaningful height effect in children.
What they found: Meclizine increased longitudinal skeletal growth in genetically modified mice carrying an ACH-like FGFR3 mutation.
Why that could mean more height:
This is the first big step beyond cells. Instead of merely showing that meclizine changes chondrocytes in a dish, they showed that an entire growing animal developed more longitudinal skeletal growth.
For humans, that would translate primarily into longer limbs and potentially greater standing height.
The important limitation: mice aren't humans, and a skeletal-growth effect in mice doesn't guarantee a clinically meaningful height effect in children.
Study: Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia.
What they found: Meclizine at doses intended to be relevant to clinical use promoted longitudinal bone growth and also affected bone volume/trabecular bone quality.
Why that could mean more height:
This strengthened the argument that the effect wasn't merely some enormous experimental dose that would never be usable in humans.
This is particularly interesting because it suggested the drug could potentially improve multiple aspects of skeletal development, not simply increase bone length.
But again, it's still animal evidence.
What they found: Meclizine at doses intended to be relevant to clinical use promoted longitudinal bone growth and also affected bone volume/trabecular bone quality.
Why that could mean more height:
This strengthened the argument that the effect wasn't merely some enormous experimental dose that would never be usable in humans.
This is particularly interesting because it suggested the drug could potentially improve multiple aspects of skeletal development, not simply increase bone length.
But again, it's still animal evidence.
Human studies
Study: Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia.
12 children, ages 5–10.
What they found: Meclizine was absorbed, produced measurable blood concentrations, and was generally well tolerated after the studied doses. The study wasn't designed to demonstrate increased height.
Why this matters for height:
This study doesn't really demonstrate growth itself.
Instead, it answers an important prerequisite:
They found that it was.
So theoretically:
oral meclizine → absorbed into blood → reaches tissues → potentially reaches growth plates → FGFR3 inhibition → possible increased growth.
But this study cannot tell us whether that actually happened to a meaningful degree in height.
12 children, ages 5–10.
What they found: Meclizine was absorbed, produced measurable blood concentrations, and was generally well tolerated after the studied doses. The study wasn't designed to demonstrate increased height.
Why this matters for height:
This study doesn't really demonstrate growth itself.
Instead, it answers an important prerequisite:
If meclizine needs to reach the growth plate to affect FGFR3 signaling, you first need the drug to be absorbed into the bloodstream.
They found that it was.
So theoretically:
oral meclizine → absorbed into blood → reaches tissues → potentially reaches growth plates → FGFR3 inhibition → possible increased growth.
But this study cannot tell us whether that actually happened to a meaningful degree in height.
Study: Phase 1b study on the repurposing of meclizine hydrochloride for children with achondroplasia.
This was another small pediatric study focused primarily on safety and pharmacokinetics.
What they found: The studied repeated doses were generally tolerated, providing additional information for moving toward an efficacy trial.
Why that could theoretically lead to height growth:
This is essentially the bridge between:
"The drug works in cells/mice"
and
"Let's give it to children long enough to see whether they grow differently."
The theoretical mechanism hadn't changed:
meclizine exposure → FGFR3 signaling suppression → less inhibition of growth-plate chondrocytes → potentially greater longitudinal growth.
But there's an important distinction:
Phase 1b established that the drug could be studied in children; it didn't establish that children become taller because of it.
This was another small pediatric study focused primarily on safety and pharmacokinetics.
What they found: The studied repeated doses were generally tolerated, providing additional information for moving toward an efficacy trial.
Why that could theoretically lead to height growth:
This is essentially the bridge between:
"The drug works in cells/mice"
and
"Let's give it to children long enough to see whether they grow differently."
The theoretical mechanism hadn't changed:
meclizine exposure → FGFR3 signaling suppression → less inhibition of growth-plate chondrocytes → potentially greater longitudinal growth.
But there's an important distinction:
Phase 1b established that the drug could be studied in children; it didn't establish that children become taller because of it.
Study: Efficacy and Safety of Oral Meclizine for Growth Promotion in Children with Achondroplasia: A Phase 2 Clinical Trial.
Nine children received meclizine for 26 weeks while also receiving growth hormone.
4.35 → 4.46 cm/year
That's only about +0.11 cm/year.
Only 1/9 children reached ≥6 cm/year.
Meanwhile, arm-span velocity was:
6.93 ± 2.50 cm/year
and 6/9 children reached ≥6 cm/year.
The drug could theoretically be affecting the skeleton, but not necessarily producing a large immediate increase in standing height.
For example, if FGFR3 inhibition affects different growth plates differently, you could see:
more upper-limb growth → increased arm span
without seeing an equivalent increase in:
femur + tibia + other contributors → standing height.
That's essentially what makes the Phase 2 result intriguing rather than simply useless.
The authors found a much stronger signal in arm-span growth than height growth.
And the study was:
But we also can't honestly say the Phase 2 study demonstrated a meaningful height benefit.
This is currently the biggest con in the meclizine-height theory.
Nine children received meclizine for 26 weeks while also receiving growth hormone.
What happened?
Height velocity:4.35 → 4.46 cm/year
That's only about +0.11 cm/year.
Only 1/9 children reached ≥6 cm/year.
Meanwhile, arm-span velocity was:
6.93 ± 2.50 cm/year
and 6/9 children reached ≥6 cm/year.
Why could it still theoretically increase height?
This is where things get interesting.The drug could theoretically be affecting the skeleton, but not necessarily producing a large immediate increase in standing height.
For example, if FGFR3 inhibition affects different growth plates differently, you could see:
more upper-limb growth → increased arm span
without seeing an equivalent increase in:
femur + tibia + other contributors → standing height.
That's essentially what makes the Phase 2 result intriguing rather than simply useless.
The authors found a much stronger signal in arm-span growth than height growth.
But here's the problem
The actual human height result was weak.And the study was:
- only 9 children
- only 26 weeks
- open-label
- single-arm
- no placebo group
- all participants were also receiving GH
But we also can't honestly say the Phase 2 study demonstrated a meaningful height benefit.
This is currently the biggest con in the meclizine-height theory.
7. Vosoritide — useful comparison
Study: C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.This isn't a meclizine study. I'm including it because it gives you a really useful "what successful FGFR3-targeted growth treatment looks like in humans" comparison.
Vosoritide works through a different pathway that essentially counteracts the downstream growth-suppressing effects of FGFR3.
In the study, growth velocity increased by roughly 1.3–2.1 cm/year above baseline at 6 months in several dose groups, and the increase was maintained for years. Height Z-scores also improved.
Why could that increase height?
Very simplified:FGFR3 overactivity → MAPK pathway overactivity → growth-plate suppression
while CNP/vosoritide activates:
NPR-B → cGMP → PKG → inhibition of the FGFR3/MAPK growth-suppressing pathway
So you get:
less FGFR3 braking → more growth-plate activity → increased longitudinal bone growth → increased height.
That's conceptually similar to why meclizine is interesting, even though the molecular route is different.
And importantly, vosoritide provides actual human evidence that interfering with the FGFR3 growth-suppression pathway can increase linear growth.
This is another useful comparison rather than a meclizine study.
The randomized trial included 84 children and compared weekly navepegritide with placebo.
At 52 weeks:
The basic idea is:
FGFR3 = accelerator on the growth-suppression system
CNP/NPR-B pathway = counterweight to that suppression
So increasing CNP signaling can partially release the growth plate from FGFR3's brake.
That's why these newer drugs are useful comparisons for meclizine: they demonstrate that the biological target itself is legitimate.
The question for meclizine is whether its particular way of interfering with FGFR3 signaling is strong enough in humans to produce the same kind of linear-growth effect.
The randomized trial included 84 children and compared weekly navepegritide with placebo.
At 52 weeks:
- Navepegritide: 5.89 cm/year
- Placebo: 4.41 cm/year
- Difference: 1.49 cm/year
- 95% CI: 1.05–1.93
- P < .001
Why can it theoretically increase height?
Again, it's a CNP-pathway strategy.The basic idea is:
FGFR3 = accelerator on the growth-suppression system
CNP/NPR-B pathway = counterweight to that suppression
So increasing CNP signaling can partially release the growth plate from FGFR3's brake.
That's why these newer drugs are useful comparisons for meclizine: they demonstrate that the biological target itself is legitimate.
The question for meclizine is whether its particular way of interfering with FGFR3 signaling is strong enough in humans to produce the same kind of linear-growth effect.
So according to my research this definitely correlates with height, the issue is that there isn't enough evidence that meclizine inhibits FGFR3 strongly enough, long enough, in the right tissues to produce a meaningful increase in human standing height. Also according to my evidence you're highly likely to get a lot of arm-span growth while on meclizine.
Would it work if you take it?
It should theoretically work fine since the arm-span increase means that meclizine is capable of increasing your eventual height, but we don't have enough human evidence showing that it could although it biologically should work.Dosage:
There isn't an exact dosage you should take due to the lack of evidence but according to the studies, the theoretical best dosage for height growth would be somewhere around 25mg so I'd aim for there.
Side effects:
- Drowsiness/somnolence
- Fatigue
- Dry mouth
- Headache
- Vomiting
- Blurred vision, rarely
- Allergic/anaphylactic reactions, rarely
(You can dnr ts its just regular stores)
Sourcing:
- Walmart
- HealthWarehouse
- Target
- CVS Pharnacy
Does it cause cognitive numbing?
I don't know who said this but that's a myth meclizine doesn't cause permanent cognitive numbing it can cause drowsiness/somnolence temporarily.
